Öz
Bisfosfonatlar (BP’ler), iyi bilinen anti-rezorptif etkileri nedeniyle, osteoporoz tedavisinde tercih edilen ilk ilaçlardandır. Bazı çalışmalara göre, immün modülasyon, anti-enflamatuvar etki ile romatolojik hastalıklarda yapısal eklem hasarının önlemede de işlev görebilecekleri bildirilmiştir. BP’lerin romatolojik hastalıkların tedavisinde kullanılabileceğine dair bu umut verici sonuçlara rağmen, çok sayıda rapor, ilaçların artrit gelişimine katkıda bulunan bir faktör olduğuna işaret etmektedir. Zoledronik asit kullanımına bağlı el bilek artriti ve parmağında daktilit gelişen sırasıyla 71 ve 55 yaşında iki hasta sunulacaktır. Bu çalışma, hastamızın zoledronik asit uygulaması sonrası daktilit tanısı alan ilk olgu olması ve diğer olgumuzun da literatürde zoledronik asit uygulaması sonrası oligoartiküler eklem tutulumu görülen birkaç olgudan biri olması nedeniyle önemlidir.
Anahtar Kelimeler: Anahtar kelimeler: Artrit, bifosfonatlar, daktilit
Kaynakça
Peris P, Monegal A, Guañabens N. Bisphosphonates in inflammatory rheumatic diseases. Bone. 2021;146:115887.
Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch Intern Med. 2005;165:346-7.
Watts NB. Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metabol. 2014;58:523-9.
Gehrke B, Alves Coelho MC, Brasil d’Alva C, Madeira M. Long-term consequences of osteoporosis therapy with bisphosphonates. Arch Endocrinol Metab. 2023;68:e220334.
Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369-76.
Khan AA, Kaiser S. Atypical femoral fracture. CMAJ. 2017;189:E542.
Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, et al. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int. 1997;61:386-92.
Giusti A, Camellino D, Saverino D, Iervasi E, Girasole G, Bianchi G, et al. Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption. Bone. 2020;138:115512.
Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D, et al. A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther. 2009;11:R185.
Xie Z, Liu G, Tang P, Sun X, Chen S, Qin A, et al. Bone-targeted methotrexate-alendronate conjugate inhibits osteoclastogenesis in vitro and prevents bone loss and inflammation of collagen-induced arthritis in vivo. Drug Deliv. 2018;25:187-97.
Lee H, Bhang SH, Lee JH, Kim H, Hahn SK. Tocilizumab-Alendronate Conjugate for Treatment of Rheumatoid Arthritis. Bioconjug Chem. 2017;28:1084-92.
Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017;84:213-5.
Roddy E, Muller S, Paskins Z, Hider SL, Blagojevic-Bucknall M, Mallen CD. Incident acute pseudogout and prior bisphosphonate use: Matched case-control study in the UK-Clinical Practice Research Datalink. Medicine (Baltimore). 2017;96:e6177.
Kleiber Balderrama C, Rosenthal AK, Lans D, Singh JA, Bartels CM. Calcium Pyrophosphate Deposition Disease and Associated Medical Comorbidities: A National Cross-Sectional Study of US Veterans. Arthritis Care Res (Hoboken). 2017;69:1400-6.
The Uppsala Monitoring Centre. Alendronic acid and synovitis. Signal, March 2003. (Restricted document. Contact the Uppsala Monitoring Centre for details; e-mail:info@who-umc.org.
Gwynne Jones DP, Savage RL, Highton J. Alendronate-induced synovitis. J Rheumatol. 2008;35:537-8.
Frederiksen L, Junker P, Brixen KT. Persisterende polyartikulaer synovitis efter behandling med alendronat [Persistent polyarticular synovitis after treatment with alendronate]. Ugeskr Laeger. 2007;169:1583-4.
Uğurlar M. Alendronate- and risedronate-induced acute polyarthritis. Osteoporos Int. 2016;27:3383-5.
Jones DG, Savage R, Highton J. Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ. 2005;330:74.
Yemisci OU, Yalbuzdag SA, Karatas M. Risedronate-induced arthritis. J Clin Rheumatol. 2010;16:168-9.
Diaz-Borjon A, Seyler TM, Chen NL, Lim SS. Bisphosphonate-associated arthritis. J Clin Rheumatol. 2006;12:131-3.
Werner de Castro GR, Neves FS, de Magalhães Souza Fialho SC, Pereira IA, Ribeiro G, Zimmermann AF. Flare-up of hand osteoarthritis caused by zoledronic acid infusion. Osteoporos Int. 2010;21:1617-9.
White SL, Jacob A, Gregson C, Bhalla A. Severe polyarthritis secondary to zolendronic acid: a case report and literature review. Clin Cases Miner Bone Metab. 2015;12:69-74.
